Overview
Bob Moens is a co-founder of moveUP - digital therapies, where he has been Director Sales & Marketing since November 2018. He is based in Leuven. Since January 2023 he has also been general manager of moveUP Labs, and since September 2018 he has held a MedTech and digital health executive role at Excellerator. Between November 2018 and February 2022 he worked on market development for Belgium and the UK at SkinVision.
Before that, Moens spent time at Medtronic, first as business manager for the cardiovascular group from August 2015 and then as business manager neurovascular until July 2018. He joined Covidien in November 2007 as marketing manager surgical and became business unit director in May 2010, remaining until July 2015. Earlier roles include business consultant at TforG, business manager at Abbott Point of Care, product manager spine surgery at Kyphon Europe, management trainee at ORMIT BeLux N.V. and sales representative at Synthes.
He studied physical therapy at Ghent University, completing a master's degree in 1996, followed by business administration at KU Leuven and the Middle Management Program at Vlerick Business School.
Career history
In the news
- Last week I attended European Association for the Study of Diabetes e.V. (EASD) in Milan, the European congress on diabetes, both type 1 and type 2. With over 16,000 attendees, it’s the largest diabetes meeting in the world! It’s fascinating to see how far the new combined technologies already go: a CGM (Continuous Glucose Monitor) measures the glucose level, and an insulin pump automatically delivers the dose the patient needs. But the real & positive shift is towards prevention. More than 60 sessions at the congress were about
- Ken jij het verschil tussen type 1- en type 2-diabetes? En waarom is vroegtijdige screening op type 1-diabetes zo belangrijk? Type 2-diabetes ontstaat meestal geleidelijk door insulineresistentie en hangt samen met verschillende factoren, waaronder genetica, leeftijd, gewicht en leefstijl. Maar daar gaat deze post niet over 😊 Type 1-diabetes (T1D) is een auto-immuunziekte waarbij het lichaam stopt met insuline produceren. Hoewel T1D slechts 5 tot 10% van alle diabetesgevallen vertegenwoordigt, is de impact voor kinderen en
- Thank you Andrew S. Rhinehart, MD for summarising this and your work in California on T1 Diabetes screening. This is also the moment to congratulate the teams at BEAT-T1D (Belgian Early Awareness and Testing for T1D) and Fondation Francophone pour la Recherche sur le Diabète - FFRD INNODIA and in specific kudos to chantal mathieu Olivier Pollé Gaëtan Haenecour Roberto Mallone Clara Domingo-Vila Manuela Battaglia Gert-Jan Dossche for their visionary work and research in the early screening for T1D. At Cascador / moveUP we are very
- Day 2 at #EAN2026, the European Academy of Neurology Congress, in Geneva, where despite the mountains & lake, it was also 34 degrees yesterday 😅 6 key observations so far: 1/ AI has become mainstream. Last year everyone talked about it. This year it's embedded in clinical decision-making... and, judging by the presentations, probably helped create most slide decks too. 😉 2/ Great to meet neurologists using our engagement & monitoring solutions in Myasthenia Gravis, Multiple Sclerosis and Migraine. Nothing beats hearing
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.